Last reviewed · How we verify
NCT07074210
Value of Volume Oxygenation Index to Detect Early Failure of Non-invasive Ventilation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
trial testing non invasive ventilation in COPD in 190 participants. Not yet recruiting.
15 January 2026
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 190 |
| Start date | 15 July 2025 |
| Primary completion | 15 January 2026 |
| Estimated completion | 15 July 2026 |
Drugs / interventions tested
- non invasive ventilation
Conditions studied
- COPD — all drugs for COPD →
- Non Invasive Ventilation (NIV) — all drugs for Non Invasive Ventilation (NIV) →
- VOX Index — all drugs for VOX Index →
Sponsor
Assiut University
Who can join
18 and older, any sex, with COPD or Non Invasive Ventilation (NIV). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Non-invasive ventilation (NIV) is an evidence-based treatment for patients with acute respiratory failure due to an exacerbation of Chronic Obstructive Pulmonary Disease (COPD). In patients with COPD and acute hypercapnic respiratory failure, NIV improves gas exchange, reduces the work of breathing, and decreases the length of hospital stay and mortality \[1\]. Furthermore, when compared to invasive ventilation, NIV leads to fewer complications, such as ventilator-related infections \[2\]. These findings have resulted in guideline recommendations for the use of NIV in acute respiratory failure due to an exacerbation of COPD \[3\].NIV failure has been defined as the need for endotracheal intubation (ETI) or death. Its rate varies greatly between 5% and 60%, depending on numerous factors \[4\]. The Volume Oxygenation (VOX) index, initially developed to predict treatment failure of high flow nasal cannula therapy, has demonstrated the ability to estimate early increases in respiratory drive. Within the first 2 h, the VOX index exhibits a discriminative potential of 0.88 (95 % CI 0.79-0.97) in predicting HFNC failure \[5\]. Based on this premise, we hypothesize that the VOX index could be a predictive tool for NIV treatment failure.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07074210
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of non invasive ventilation
Trials testing the same drug.
- NCT05850195 — Assessment Of Different Indices in Prediction of Noninvasive Ventilation Failure in Patients With Acute Respiratory Fail · unknown
- NCT05189119 — Use of PARniv for Early Diagnosis of LVF in AECOPD · completed
- NCT03619499 — Non Invasive Ventilation in Bronchiolitis · NA · unknown
Other recruiting trials for COPD
Currently open trials in the same condition.
- NCT07344649 — Turkish Validation of the Nijmegen Questionnaire in COPD · recruiting
- NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
- NCT07460154 — Structured Review: To Optimise Management and Prevent Harm in COPD · NA · recruiting
- NCT07462221 — Effect of Telenursing on Oral Health · NA · recruiting
- NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07074210 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 20 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07074210.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing